drugset / Trial / NCT01199341

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

NCT01199341

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelBasic science

Summary

The primary purpose of this study is to determine whether the treatment with AZD1981 affect the exposure of Warfarin.

Timeline

Start
2010-10
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1981 Small molecule 100 mg Oral
Subject AZD1981 Small molecule 400 mg Oral
Subject Warfarin Small molecule 25 mg Oral

Indications

No indication recorded.